Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 1999, p. 2685-2688, Vol. 43, No. 11
Division of Infectious Diseases, Children's
Hospital Medical Center, Cincinnati, Ohio
Received 5 March 1999/Returned for modification 10 June
1999/Accepted 25 August 1999
Neuropharmacologic agents able to disrupt normal virus-neuron
interactions may provide an alternative strategy for the treatment of
herpes simplex virus (HSV) infections. We have previously shown that
prophylactic treatment with capsaicin, a natural compound that alters
function in sensory neurons, can protect guinea pigs against cutaneous
HSV disease, even though the compound has no direct antiviral activity.
Here we have examined the ability of civamide, the cis
isomer of capsaicin, to interfere with HSV disease. We show that, even
when the onset of treatment was delayed until after intravaginal virus
challenge, primary genital skin disease severity was significantly
reduced. In addition, animals treated during primary infection
subsequently experienced a long-lasting reduction in recurrent disease.
Civamide treatment during latent infection also significantly reduced
recurrent disease, although for a shorter period. Further a single
weekly treatment with civamide during latent infection was sufficient
to reduce recurrent disease, indicating that an infrequent suppressive
maintenance therapy might be possible.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Civamide (cis-Capsaicin) for Treatment
of Primary or Recurrent Experimental Genital Herpes
*
Corresponding author. Mailing address: Children's
Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet
Ave., Cincinnati, OH 45229. Phone: (513) 636-7666. Fax: (513) 636-7655. E-mail: bourn0{at}chmcc.org.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»